Related Experiment Video
Updated: Jun 6, 2026
09:17
Co-immunoprecipitation Assay Using Endogenous Nuclear Proteins from Cells Cultured Under Hypoxic Conditions
Published on: August 2, 2018
Chalcone-based inhibitors against hypoxia-inducible factor 1--structure activity relationship studies
Balasubramanian Srinivasan1, Thomas E Johnson, Chengguo Xing
1Department of Medicinal Chemistry, College of Pharmacy, University of Minnesota, 308 Harvard St. SE, Minneapolis MN 55455, United States.
Bioorganic & Medicinal Chemistry Letters
|November 30, 2010
Summary
This study explores chalcone compounds as inhibitors of hypoxia-inducible factor 1 (HIF-1) to improve cancer treatment. Researchers identified potent chalcone candidates and key structural modifications for HIF-1 inhibition.
Area of Science:
- Oncology
- Medicinal Chemistry
- Molecular Biology
Background:
- Tumor tissues often experience hypoxia, promoting cancer cell survival and evasion.
- Hypoxia-inducible factor 1 (HIF-1) activation is a key mechanism for tumor survival under hypoxic conditions.
- Inhibiting HIF-1 presents a potential strategy for enhancing cancer therapy.
Purpose of the Study:
- To investigate the structure-activity relationship of chalcone compounds for HIF-1 inhibition.
- To identify novel chalcone-based HIF-1 inhibitors with therapeutic potential.
- To guide the development of more effective anticancer agents targeting HIF-1.
Main Methods:
- Synthesis and screening of a diverse panel of chalcone compounds.
- Evaluation of chalcone inhibitory activity against HIF-1.
- Structure-activity relationship (SAR) analysis to identify key structural features.
Main Results:
- Several chalcone derivatives demonstrated significant HIF-1 inhibitory activity.
- Identified lead candidates with single-digit micromolar potency.
- Determined crucial structural modifications influencing HIF-1 inhibition efficacy.
Conclusions:
- Chalcones represent a promising scaffold for developing HIF-1 inhibitors.
- This research provides valuable insights into the SAR of chalcone-based HIF-1 inhibitors.
- The identified lead compounds warrant further investigation for anticancer drug development.
Related Concept Videos
01:29Indirect-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship
Indirect-acting cholinergic agonists are agents that interact with the acetylcholinesterase enzyme in the synaptic cleft, preventing the breakdown of acetylcholine into choline and acetate. Consequently, the concentration of acetylcholine in the synaptic cleft increases. These agonists can be classified into reversible and irreversible inhibitors based on their duration of action.
Reversible inhibitors display short to medium durations of action. Short-acting agents include simple alcohols with...
Reversible inhibitors display short to medium durations of action. Short-acting agents include simple alcohols with...
01:22Direct-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship
Cholinergic agonists or cholinomimetics mimic the action of acetylcholine to stimulate the parasympathetic nervous system. They are categorized into direct-acting and indirect-acting agents. The direct-acting cholinergic drugs induce the parasympathetic response by directly binding to the muscarinic or nicotine receptors. In comparison, the indirect-acting cholinergic drugs prevent acetylcholine hydrolysis, indirectly contributing to the extended parasympathetic response.
The direct-acting...
The direct-acting...
01:29Cholinergic Antagonists: Chemistry and Structure-Activity Relationship
Cholinergic antagonists bind to cholinergic receptors and limit the effects of acetylcholine and other cholinergic agonists. Based on the specific cholinergic receptor affinity, these antagonists are classified as muscarinic or nicotinic. Anticholinergics interrupt parasympathetic innervations while sympathetic innervations remain uninterrupted. Muscarinic antagonists are also called 'muscarinic antagonists', 'antimuscarinics', or 'parasympatholytics'. Nicotinic antagonists are called...
01:16Adrenergic Agonists: Chemistry and Structure-Activity Relationship
Adrenergic agonists' structure-activity relationship (SAR) determines their selectivity and efficacy. These agonists comprise a phenylethylamine moiety with an aromatic ring and an ethylamine side chain.
Aromatic ring substitutions: Substituting the aromatic ring with –OH groups at positions 3 and 4 yields catecholamines (e.g., epinephrine), which have a high affinity for adrenoceptors. Hydrogen bonding between –OH groups and receptors enhances adrenergic activity.
Separation of the aromatic...
Aromatic ring substitutions: Substituting the aromatic ring with –OH groups at positions 3 and 4 yields catecholamines (e.g., epinephrine), which have a high affinity for adrenoceptors. Hydrogen bonding between –OH groups and receptors enhances adrenergic activity.
Separation of the aromatic...
02:15Protein and Protein Structure
Proteins are one of the most abundant organic molecules in living systems and have the most diverse range of functions of all macromolecules. Proteins may be structural, regulatory, contractile, or protective. They may serve in transport, storage, or membranes; or they may be toxins or enzymes. Their structures, like their functions, vary greatly. They are all, however, amino acid polymers arranged in a linear sequence.
A protein's shape is critical to its function. For example, an enzyme can...
A protein's shape is critical to its function. For example, an enzyme can...
01:28Structure-Activity Relationships and Drug Design
Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence its...
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence its...